Table 2 Baseline demographic and clinical characteristics of patients with newly-diagnosed, previously untreated multiple myeloma enrolled in phase I study of siltuximab in combination with RVD (N=11)

From: Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

Characteristic

No.

%

Age

 ⩽65 years

7

63.6

 >65 years

4

36.4

Sex

 Male

4

36.4

 Female

7

63.6

Race

 Caucasian

9

81.8

 African American

2

18.2

ISS stage

 I

7

63.6

 II

2

18.2

 III

2

18.2

ECOG performance score

 0

6

54.5

 1

5

45.5

Cytogenetics karyotype

 Normal/Diploid

4

36.4

 Loss/del 13a

2

18.2

 Hyperdiploidb

2

18.2

 t(11;14)

1

9.1

 Other

1

18.2

 Unknown

1

9.1

  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System for multiple myeloma; RVD, lenalidomide, bortezomib, dexamethasone.
  2. aIncludes one in combination with del 17p.
  3. bAlone or in combination with other cytogenetic abnormality.
Back to article page